FDA Approves Roche Meds for Rare Blood, Lung Cancers

Nov 07, 2017

The U.S. Food and Drug Administration has given Roche approval to market its skin cancer drug Zelboraf and its lung cancer drug Alecensa.

Zelboraf is now approved for certain patients, those whose cancer cells have a genetic mutation known as BRAF V600, with rare blood cancer Erdheim-Chester Disease. It is the first FDA-approved treatment for the disease.

Alecensa has been approved as initial treatment for patients with a rare form of non-small cell lung cancer caused by a mutation to a gene known as ALK.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments